The division chief of vascular neurology at the University of Utah discussed the individual role that clinicians and neurologists can play to increase interest in the field of neurology. [WATCH TIME: 2 minutes]
The Meta A. Neumann Professor of Neurology at George Washington University provided an overview of a new phase 3 study testing the efficacy and safety of cladribine versus placebo in generalized myasthenia gravis. [WATCH TIME: 3 minutes]
The assistant professor of neurology at the Keck School of Medicine at University of Southern California discussed the importance of having additional agents to treat Parkinson disease.
The neurologist at Cleveland Clinic’s Lou Ruvo Center for Brain Health detailed new findings on whether initial cognitive symptoms have similar rates of functional decline across a handful of neurodegenerative disorders. [WATCH TIME: 3 minutes]
The neuropsychologist and assistant professor of neurology at the University of California, San Francisco Memory and Aging Center provided comment on her presentation from AAN 2024 examining the association of area deprivation index with cognitive functioning in Black women. [WATCH TIME: 3 minutes]
The director of the Dartmouth Epilepsy Program provided an overview of some of the critical unmet needs within ongoing epilepsy research following the recent AES Annual Meeting.
Nina Miolane, PhD, and Amy Kuceyeski, PhD, the codirectors of the Ann S. Bowers Women's Brain Health Initiative AI Core, provided their commentary on the challenges and progress made in women’s neurology.
Sucheta M. Joshi, MD, MS, FAES, FAAP, and Nicholas Beimer, MD, discussed the reasons why EpiTRAQ may influence earlier discussions with patients prior to the epilepsy transition process.
A trio of experts talked about Lexeo Therapeutics’ LX1001 gene therapy trial that demonstrated promising safety and biomarker effects in patients with early-stage Alzheimer disease. [WATCH TIME: 5 minutes]
The clinical professor of neurology at Stanford University School of Medicine talked about the collaboration of Rapport leveraging NeuroPace’s data analysis capabilities to study the target delivery of a therapy for focal epilepsy. [WATCH TIME: 5 minutes]
The neurologist at University of Utah discussed the potential of using teleneurology to diagnose neurological conditions.
The senior VP of clinical research at Eisai discussed findings from a phase 2 study assessing irsenontrine in patients with dementia with Lewy bodies and Parkinson disease dementia. [WATCH TIME: 4 minutes]
Mindy K. Bixby, DO and Laxman Bahroo, DO give key advice to community neurologists and emphasize the importance of effective communication between patients and providers.
Episode 7 of the AUPN Leadership Minute features Donald S. Higgins Jr., MD, of the VHA; and Justin C. McArthur, MBBS, MPH, of Johns Hopkins University. [WATCH TIME: 4 minutes]
The associate professor of neurochemistry at the University of Gothenburg in Sweden talked about a pilot study that explored the potential of finger prick tests to remotely collect blood and provide reliable biomarker results for Alzheimer disease diagnosis. [WATCH TIME: 5 minutes]
The professor of neurology and pediatrics at the University of Alabama at Birmingham Epilepsy Center provided perspective on the strides made with detection and treatment of infantile spasms. [WATCH TIME: 3 minutes]
The professor of pediatrics at Case Western University discussed the complexities and negative effects for children drastically change their sleep schedules as school begins. [WATCH TIME: 3 minutes]
There should be a holistic approach to how the systems in place affect equity: how medicine is practiced and research is conducted, the structure of academic institutions, and how media influence our perceptions of neurologic conditions.
The director of the Center for Sleep and Cardiovascular Outcomes Research at University of Pittsburgh talked about a novel pharmacologic treatment that shows potential as an alternative to continuous positive airway pressure for sleep apnea. [WATCH TIME: 5 minutes]
The professor of materials science and engineering at Cornell University and chief executive officer at Artificial Axon Labs talked about the development of artificial axons through 3D printing. [WATCH TIME: 6 minutes]
Neurology experts discuss the unmet needs in narcolepsy treatment and share clinical pearls from their experiences.
The associate professor of pediatrics at the University of Colorado School of Medicine talked at the 2023 MDA Conference about how digestive health impacts patients with Duchene Muscular Dystrophy. [WATCH TIME: 4 minutes]
The professor of emergency medicine at Washington University in St. Louis and associate professor of neurosurgery at UTHealth Houston talked about results from the phase 3 MOST trial assessing argatroban and eptifibatide in acute ischemic stroke. [WATCH TIME: 3 minutes]
The internal medicine physician and chief medical officer and head of development at Pear Therapeutics offered his perspective on the current focus that is given to sleep in clinical care and the lack of education on interventions. [WATCH TIME: 2 minutes]
The chief medical officer at Alzheon provided perspective on the next steps for ALZ-801 following a successful phase 2 study of patients with APOE ε4/4 or APOE ε3/4 genotype. [WATCH TIME: 2 minutes]
The head of Global Medical for Neuropsychiatry and Alzheimer Disease at Biogen commented on challenges with conducting effective trials for Alzheimer disease and the potential research opportunities with newly approved novel treatments. [WATCH TIME: 6 minutes]
As many as 1 in 3 infected with COVID-19 have longer-term neurological or mental health symptoms.
The chairman of the Clinical Advisory Committee of the New England Chapter of the National MS Society addressed the role DMTs play in patient response to the COVID-19 vaccine.
The clinical assistant professor of neurology at Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, New York, talked about her presentation on Evusheld at the 2023 ACTRIMS Forum. [WATCH TIME: 5 minutes]
The assistant director of computational biology at Stanford University discussed where the Alzheimer disease community stands on gene therapies that target APOE, and whether missense variants will play a role. [WATCH TIME: 4 minutes]